NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors

Kensuke Nakagawara1,2, Makoto Ando2, Tanakorn Srirat2

  • 1Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan yoshimura@keio.jp k.nakagawara@keio.jp.

Abstract

Insights

Deleting NR4A factors enhances chimeric antigen receptor (CAR)-T cell effectiveness against solid tumors. NR4A triple knockout CAR-T cells resist exhaustion and improve antitumor activity by boosting mitochondrial function.

Area of Science:

  • Immunology
  • Cancer Biology
  • Cellular Engineering

Background:

  • Chimeric antigen receptor (CAR)-T cell therapy faces challenges in solid tumors, including T cell exhaustion.
  • NR4A transcription factors are implicated in T cell exhaustion, but their role in human CAR-T cells requires clarification.

Purpose of the Study:

  • To investigate the role of NR4A transcription factors in human CAR-T cell differentiation and exhaustion.
  • To evaluate the potential of NR4A deletion in enhancing CAR-T cell antitumor activity against solid tumors.

Main Methods:

  • Human CAR-T cells targeting HER2 were engineered using CRISPR/Cas9 to delete NR4A1, NR4A2, and NR4A3.
  • T cell exhaustion was induced in vitro, and NR4A-knockout CAR-T cells were assessed for phenotype, proliferation, cytokine production, and metabolic activity.
  • Antitumor toxicity of NR4A triple knockout (TKO) CAR-T cells was validated in vivo using a lung adenocarcinoma xenograft model.

Main Results:

  • NR4A-TKO CAR-T cells exhibited resistance to exhaustion and maintained superior tumor-killing activity in vitro and in vivo compared to control CAR-T cells.
  • Triple knockout of NR4A factors was most effective in preventing T cell exhaustion.
  • Enhanced antitumor effects were observed in CAR-T cells from diverse donors, including aged individuals.
  • NR4A-TKO CAR-T cells demonstrated increased mitochondrial oxidative phosphorylation, leading to prolonged persistence in tumors.

Conclusions:

  • NR4A factors critically regulate CAR-T cell persistence and stemness via mitochondrial gene expression.
  • Targeting NR4A offers a promising strategy for developing enhanced CAR-T cells for solid tumor treatment.